Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Tuesday, down -1.32% from the previous trading day, before settling in for the closing price of $6.83. Over the past 52 weeks, RLAY has traded in a range of $5.95-$18.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 319.82% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -3.44%. With a float of $92.21 million, this company’s outstanding shares have now reached $127.46 million.
In an organization with 323 employees, it is important to assess its efficiency.
Relay Therapeutics Inc (RLAY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 29.71%, while institutional ownership is 71.73%. The most recent insider transaction that took place on Mar 27 ’24, was worth 5,890. In this transaction President, R&D of this company sold 765 shares at a rate of $7.70, taking the stock ownership to the 530,113 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Financial Officer sold 348 for $7.70, making the entire transaction worth $2,680. This insider now owns 341,498 shares in total.
Relay Therapeutics Inc (RLAY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 12.40 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.44% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 25.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 34.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.79, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -2.83 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Let’s dig in a bit further. During the last 5-days, its volume was 0.91 million. That was inferior than the volume of 1.1 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.29%. Additionally, its Average True Range was 0.46.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 2.17%, which indicates a significant decrease from 6.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.61% in the past 14 days, which was higher than the 58.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.76, while its 200-day Moving Average is $9.51. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $6.95. Second resistance stands at $7.17. The third major resistance level sits at $7.33. If the price goes on to break the first support level at $6.57, it is likely to go to the next support level at $6.41. The third support level lies at $6.19 if the price breaches the second support level.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 884.15 million has total of 131,179K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 25,200 K and last quarter income was -65,730 K.
